Components prepared from whole blood* | |
Hepatitis B virus[1,2] | 1:1 million to 1:1.5 million |
Hepatitis C virus[1,2] | 1:2 million to 1:2.6 million |
HTLV[3,4] | 1:2.7 million |
HIV[1,2] | 1:1.6 million to 1:2.3 million |
Solvent/detergent-treated plasma products | |
Hepatitis C virus | Inactivated |
Hepatitis B virus | Inactivated |
HIV | Inactivated |
Hepatitis A virus | Not fully inactivated¶ |
Parvovirus B19 | Not fully inactivated¶ |
Hepatitis E virus | Not fully inactivated¶ |
Platelets | |
With automated bacterial culturing methods in place, septic transfusion reactions are estimated to occur at a rate of 1:50,000 to 1:80,000 transfused platelet apheresis units. This is an underestimate since it relies on passive surveillance data[5]. | |
CMV infection | |
The risk of CMV infection is rare in recipients with selected conditions (eg, bone marrow or solid organ transplants) who are at risk for severe morbidity from CMV infection and who receive CMV reduced-risk products. Two methods to supply CMV reduced-risk products that appear to have equal efficacy are CMV-seronegative cellular components (red blood cells, platelets) or leukoreduced components. |
Do you want to add Medilib to your home screen?